newsfilter
← Latest News
GlobeNewswire·

Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand growth on track